{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:40:23Z","timestamp":1774550423522,"version":"3.50.1"},"reference-count":43,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2012]]},"DOI":"10.1248\/bpb.b12-00298","type":"journal-article","created":{"date-parts":[[2012,10,31]],"date-time":"2012-10-31T22:41:36Z","timestamp":1351723296000},"page":"1932-1940","source":"Crossref","is-referenced-by-count":5,"title":["Involvement of Phosphatidylinositol 3-Kinase\/Akt Pathway in Gemcitabine-Induced Apoptosis-Like Cell Death in Insulinoma Cell Line INS-1"],"prefix":"10.1248","volume":"35","author":[{"given":"Hironori","family":"Motoshige","sequence":"first","affiliation":[{"name":"Division of Biochemistry, Department of Life Science, School of Pharmacy, Hokkaido Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyohei","family":"Oyama","sequence":"additional","affiliation":[{"name":"Division of Biochemistry, Department of Life Science, School of Pharmacy, Hokkaido Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Biochemistry, Department of Life Science, School of Pharmacy, Hokkaido Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Division of Biochemistry, Department of Life Science, School of Pharmacy, Hokkaido Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Lenz HJ. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat. Rev.<\/i>, 29<\/b> (Suppl. 1), 41–48 (2003)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hilbig A, Oettle H. Gemcitabine in the treatment of metastatic pancreatic cancer. Expert Rev. Anticancer Ther.<\/i>, 8<\/b>, 511–523 (2008).","DOI":"10.1586\/14737140.8.4.511"},{"key":"3","doi-asserted-by":"crossref","unstructured":"4) Sigmond J, Kamphuis JAE, Laan AC, Hoebe EK, Bergman AM, Peters GJ. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. Biochem. Pharmacol.<\/i>, 73<\/b>, 1548–1557 (2007).","DOI":"10.1016\/j.bcp.2007.01.025"},{"key":"4","doi-asserted-by":"crossref","unstructured":"5) Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann. Oncol.<\/i>, 17<\/b>, v7–v12 (2006).","DOI":"10.1093\/annonc\/mdj941"},{"key":"5","doi-asserted-by":"crossref","unstructured":"6) Yin T, Wei H, Gou S, Shi P, Yang Z, Zhao G, Wang C. Cancer stem-like cells enriched in panc-1 spheres possess increased migration ability and resistance to gemcitabine. Int. J. Mol. Sci.<\/i>, 12<\/b>, 1595–1604 (2011).","DOI":"10.3390\/ijms12031595"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7) Pasetto LM, D’Andrea MR, Falci C, Monfardini S. Gemcitabine in advanced biliary tract cancers. Crit. Rev. Oncol. Hematol.<\/i>, 61<\/b>, 230–242 (2007).","DOI":"10.1016\/j.critrevonc.2006.04.006"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8) Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res.<\/i>, 12<\/b>, 9–18 (2002).","DOI":"10.1038\/sj.cr.7290105"},{"key":"8","unstructured":"10) Krasilnikov MA. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry<\/i> (Mosc.), 65<\/b>, 59–67 (2000), Mosc."},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20040167"},{"key":"10","doi-asserted-by":"crossref","unstructured":"12) Kao J, Sikora AT, Fu S. Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. Curr. Cancer Drug Targets<\/i>, 9<\/b>, 931–937 (2009).","DOI":"10.2174\/156800909790192437"},{"key":"11","doi-asserted-by":"crossref","unstructured":"13) Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist<\/i>, 16<\/b>, 404–414 (2011).","DOI":"10.1634\/theoncologist.2010-0402"},{"key":"12","doi-asserted-by":"crossref","unstructured":"15) Wang YA, Johnson SK, Brown BL, McCarragher LM, Al-Sakkaf K, Royds JA, Dobson PR. Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. Int. J. Cancer<\/i>, 123<\/b>, 1536–1544 (2008).","DOI":"10.1002\/ijc.23671"},{"key":"13","doi-asserted-by":"crossref","unstructured":"16) Shea JE, Nam KH, Rapoport N, Scaife CL. Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma. HPB<\/i> (Oxford), 13<\/b>, 153–157 (2011), Oxford.","DOI":"10.1111\/j.1477-2574.2010.00249.x"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.9514"},{"key":"15","unstructured":"19) Tsao MS, Chow S, Hedley DW, Ng SSW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res.<\/i>, 60<\/b>, 5451–5455 (2000)."},{"key":"16","unstructured":"20) Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro<\/i> and in vivo<\/i>. Mol. Cancer Ther.<\/i>, 1<\/b>, 989–997 (2002)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"21) Okada S, Ueno H, Okusaka T, Ikeda M, Furuse J, Maru Y. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn. J. Clin. Oncol.<\/i>, 31<\/b>, 7–12 (2001).","DOI":"10.1093\/jjco\/hye003"},{"key":"18","doi-asserted-by":"crossref","unstructured":"22) Pigeau GM, Kolic J, Ball BJ, Hoppa MB, Wang YW, Rückle T, Woo M, Manning Fox JE, MacDonald PE. Insulin granule recruitment and exocytosis is dependent on p110gamma in insulinoma and human beta-cells. Diabetes<\/i>, 58<\/b>, 2084–2092 (2009).","DOI":"10.2337\/db08-1371"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.3.1660"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1210\/en.130.1.167"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.24.876"},{"key":"22","doi-asserted-by":"crossref","unstructured":"28) Sakurai K, Cederbaum AI. Oxidative stress and cytotoxicity induced by ferric-nitrilotriacetate in HepG2 cells that express cytochrome P450 2E1. Mol. Pharmacol.<\/i>, 54<\/b>, 1024–1035 (1998).","DOI":"10.1124\/mol.54.6.1024"},{"key":"23","unstructured":"30) Gupta M, Fan S, Zhan Q, Kohn KW, O’Connor PM, Pommier Y. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin. Cancer Res.<\/i>, 3<\/b>, 1653–1660 (1997)."},{"key":"24","unstructured":"31) Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. Cancer Invest.<\/i>, 21<\/b>, 489–496 (2003)."},{"key":"25","doi-asserted-by":"crossref","unstructured":"32) Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab. Rev.<\/i>, 41<\/b>, 77–88 (2009).","DOI":"10.1080\/03602530902741828"},{"key":"26","unstructured":"34) Wang Q, Li N, Wang X, Kim MM, Evers BM. Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3′-kinase inhibition in the KM20 human colon cancer cell line. Clin. Cancer Res.<\/i>, 8<\/b>, 1940–1947 (2002)."},{"key":"27","doi-asserted-by":"crossref","unstructured":"37) Hohenester S, Gates A, Wimmer R, Beuers U, Anwer MS, Rust C, Webster CR. Phosphatidylinositol-3-kinase p110γ contributes to bile salt-induced apoptosis in primary rat hepatocytes and human hepatoma cells. J. Hepatol.<\/i>, 53<\/b>, 918–926 (2010).","DOI":"10.1016\/j.jhep.2010.05.015"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1042\/0264-6021:3580481"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.23.7.2407-2414.2003"},{"key":"30","doi-asserted-by":"crossref","unstructured":"40) Lee SB, Cho ES, Yang HS, Kim H, Um HD. Serum withdrawal kills U937 cells by inducing a positive mutual interaction between reactive oxygen species and phosphoinositide 3-kinase. Cell. Signal.<\/i>, 17<\/b>, 197–204 (2005).","DOI":"10.1016\/j.cellsig.2004.07.001"},{"key":"31","doi-asserted-by":"crossref","unstructured":"41) Lim SC, Duong HQ, Choi JE, Parajuli KR, Kang HS, Han SI. Implication of PI3K-dependent HSP27 and p53 expression in mild heat shock-triggered switch of metabolic stress-induced necrosis to apoptosis in A549 cells. Int. J. Oncol.<\/i>, 36<\/b>, 387–393 (2010).","DOI":"10.3892\/ijo_00000511"},{"key":"32","unstructured":"43) Nishimoto S, Nishida E. MAPK signalling: ERK5 versus<\/i> ERK1\/2. EMBO Rep.<\/i>, 7<\/b>, 782–786 (2006)."},{"key":"33","unstructured":"44) Fukazawa H, Uehara Y. U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways. Cancer Res.<\/i>, 60<\/b>, 2104–2107 (2000)."},{"key":"34","doi-asserted-by":"crossref","unstructured":"45) Takahashi K, Sakurai K, Takahashi K, Tanaka H, Fujimoto Y. Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde. Anticancer Drugs<\/i>, 18<\/b>, 543–553 (2007).","DOI":"10.1097\/CAD.0b013e328026240f"},{"key":"35","unstructured":"47) Wang Y, Dawson VL, Dawson TM. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp. Neurol.<\/i>, 218<\/b>, 193–202 (2009)."},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1573"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2007.11.001"},{"key":"38","doi-asserted-by":"crossref","unstructured":"50) Mukubou H, Tsujimura T, Sasaki R, Ku Y. The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation. Int. J. Oncol.<\/i>, 37<\/b>, 821–828 (2010).","DOI":"10.3892\/ijo_00000732"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2008.07.031"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1038\/365349a0"},{"key":"41","doi-asserted-by":"crossref","unstructured":"54) Breidenbach M, Rein DT, Schöndorf T, Schmidt T, König E, Valter M, Kurbacher CM. Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer. Anticancer Drugs<\/i>, 14<\/b>, 341–346 (2003).","DOI":"10.1097\/00001813-200306000-00003"},{"key":"42","doi-asserted-by":"crossref","unstructured":"57) Lalaoui N, Morlé A, Mérino D, Jacquemin G, Iessi E, Morizot A, Shirley S, Robert B, Solary E, Garrido C, Micheau O. TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT. PLoS ONE<\/i>, 6<\/b>, e19679 (2011).","DOI":"10.1371\/journal.pone.0019679"},{"key":"43","unstructured":"59) Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb\/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res.<\/i>, 7<\/b>, 3269–3275 (2001)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/35\/11\/35_b12-00298\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T04:33:07Z","timestamp":1615869187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/35\/11\/35_b12-00298\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b12-00298","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}